Spero Therapeutics, Inc.
SPRO
$0.71
-$0.0152-2.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.04M | 13.47M | 10.20M | 9.27M | 73.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.04M | 13.47M | 10.20M | 9.27M | 73.52M |
| Cost of Revenue | 92.51M | 703.00K | 23.73M | 17.33M | 49.43M |
| Gross Profit | -62.42M | 12.77M | -13.53M | -8.07M | 24.09M |
| SG&A Expenses | 7.06M | 5.20M | 5.53M | 5.92M | 6.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.89M | 32.06M | 29.26M | 23.25M | 22.99M |
| Operating Income | -20.85M | -18.59M | -19.06M | -13.98M | 50.53M |
| Income Before Tax | -20.60M | -17.44M | -17.86M | -12.67M | 51.58M |
| Income Tax Expenses | 290.00K | -290.00K | -- | -- | 387.00K |
| Earnings from Continuing Operations | -20.89M | -17.15M | -17.86M | -12.67M | 51.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.89M | -17.15M | -17.86M | -12.67M | 51.19M |
| EBIT | -20.85M | -18.59M | -19.06M | -13.98M | 50.53M |
| EBITDA | -20.85M | -18.59M | -19.06M | -13.89M | 50.57M |
| EPS Basic | -0.38 | -0.32 | -0.33 | -0.24 | 0.97 |
| Normalized Basic EPS | -0.23 | -0.20 | -0.21 | -0.15 | 0.61 |
| EPS Diluted | -0.38 | -0.32 | -0.33 | -0.24 | 0.96 |
| Normalized Diluted EPS | -0.23 | -0.20 | -0.21 | -0.15 | 0.61 |
| Average Basic Shares Outstanding | 54.54M | 54.12M | 53.96M | 53.52M | 53.00M |
| Average Diluted Shares Outstanding | 54.54M | 54.12M | 53.96M | 53.52M | 53.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |